Review weight change, glycemic control, gastrointestinal symptoms, hypoglycemia risk, hydration status, pancreatitis history, gallbladder symptoms, and medication adherence
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors not yet approved by the MHRA or EMA for clinical use in the UK
Women in perimenopause or menopause may be dealing with declining estrogen and testosterone that no amount of weight loss will correct
In fact, there is no well-founded scientific evidence to prove its efficacy, and its skin-lightening claims currently hinge on individual case reports or anecdotal evidence
Rotate the dose dial back to zero, then dial your actual prescribed dose by turning the dial until the correct number aligns with the dose indicator on the pen's side
Search strings used for each database are presented in Supplementary Table S2